Journals / Erciyes Tıp Dergisi / 2012 / Cilt: 34 - Sayı: 3

Gestasyonel trofoblastik hastalık tanısı almış olguların epidemiyolojik özellikleri ve tedavi yönetimleri

Epidemiologic characteristics and management of subjects who were diagnosed with trophoblastic disease

Pages
106–110
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that this could be achieved by generalizing public health services and antenatal follow-ups especially in developing communities.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate retrospectively the patients diagnosed and treated with gestational trophoblastic disease (GTD) in our clinic.
📊
Key Findings & Data:Material and Methods: Sixty-nine women diagnosed with GTD between January 1996 to December 2010 were included into the study.
💡
Conclusion & Impact:It was concluded that this could be achieved by generalizing public health services and antenatal follow-ups especially in developing communities.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate retrospectively the patients diagnosed and treated with gestational trophoblastic disease (GTD) in our clinic. Material and Methods: Sixty-nine women diagnosed with GTD between January 1996 to December 2010 were included into the study. Age, gravida, parity, abortus, curettages, job and education, consanguinous marriage, gestational age, blood groups, menarche age, type of GTD, hyperthyroidism, serum β-HCG levels before and after a week following the treatment were recorded. Results: Eleven thousand five hundred twenty-two deliveries occured and 69 cases were diagnosed with GTD. One patient, diagnosed with invasive mole, was excluded from the study because she did not follow the recommended chemotheraphy. Out of 68 patients; 37 (54.43%) patients were incomplete mole, 29 (42.63%) were complete mole, (1.47%) were invasive mole and 1 (1.47%) patient was choriocarcinoma. The treatment of 65 (95.6%) patients were curettage under general anesthesia, 2 (2.9%) were hysterectomy and 1 (1.5%) was chemotheraphy. Patients were followed with β-HCG and a minimum of six months contraception was recommended. Conclusion: The incidence of GTD was 5.9 per 1000 deliveries. Our patients had poor educational status, high parity and gravida. These factors seem to be etiologic reasons. Educating the patients and lowering the high birth rate can decrease the incidence of GTD. Gestational trophoblastic neoplasies are a group with high chemosensitivity. Early diagnosis and treatment may enable high remission rates even in malignant forms. It was concluded that this could be achieved by generalizing public health services and antenatal follow-ups especially in developing communities.

Özet

Amaç: Kliniğimizde gestasyonel trofoblastik hastalık (GTH) tanısıyla takip edilen ve tedavileri yapılan hastaların retrospektif olarak değerlendirilmesi. Gereç ve Yöntemler: Çalışmaya Ocak 1996-Aralık 2010 arasında İstanbul Taksim Eğitim ve Araştırma Hastanesi Kadın Hastalıkları ve Doğum Kliniğinde GTH tanısı konulan 69 hasta alındı. Hastaların yaş, gravida, parite, abortus ve küretaj sayıları, meslek, eğitim durumları, akraba evliliği, gebelik haftaları, kan grupları, menarş yaşları, GTHın histolojik tipi, hipertiroidi varlığı, tedavi öncesi ve sonrası serum β-HCG düzeyleri ve uygulanan tedaviler kaydedildi. Bulgular: Kliniğimizde 1996-2010 yılları arasında 11522 doğum gerçekleşti ve 69 olguya GTH tanısı konuldu. Bir vaka invaziv mol tanısı ile kemoterapi tedavisine yönlendirildi fakat hasta takip ve tedavilere devam etmediğinden çalışma dışı bırakıldı. Kalan 68 hastanın; 37si (%54,43) inkomplet mol, 29u komplet mol (%42,63), biri invaziv mol (%1,47) ve biri koryokarsinom olarak tespit edildi. Tedavi olarak 65 hastaya (%95,6) genel anestezi altında vakum küretaj, 2 hastaya (%2,9) histerektomi ve 1 hastaya (%1,5) kemoterapi uygulandı. Tüm hastalar β-HCG takibine alındı ve en az 6 ay kontrasepsiyon önerildi. Sonuç: Kliniğimizin gestasyonel trofoblastik hastalık insidansı 1000 doğumda 5,9 olarak bulundu. Hastalarımızın düşük eğitim seviyeli oluşları, yüksek gravida ve parite sayılı olmaları etyolojik nedenler arasındadır. Hastaların eğitilmesinin, gravida ve parite sayılarının azaltılmasının insidansın azaltılmasına katkısı olabileceği düşünüldü. Gestasyonel trofoblastik neoplaziler ise neoplazmlar içinde kemosensitivitesi yüksek bir gruptur. Erken tanı ve tedavi ile malign formlarında bile çok yüksek oranlarda remisyon sağlanabilmektedir. Bunun da özellikle gelişmekte olan toplumlarda toplum sağlığı hizmetlerinin ve antenatal takiplerin yaygınlaştırılması ile sağlanabileceği kanaatine varıldı.

🔖

Cite This Article

DİNÇGEZ, B., YUMRU, A. E., BOZYİĞİT, A., ÖNDEŞ, B. (2022). Gestasyonel trofoblastik hastalık tanısı almış olguların epidemiyolojik özellikleri ve tedavi yönetimleri. Erciyes Tıp Dergisi, Cilt: 34 - Sayı: 3, 106–110. https://ajindex.com/articles/502477

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tse KY, Chan KKL, Tam KF, Ngan HYS. Gestational trophoblastic disease. Obstetrics, Gynecology and Reproductive Medicine 2009; 19(4): 89-91
  2. Rangwala T, Badawi F. A profile of cases of gestational trophoblastic neoplasia at a large tertiary centre in Dubai. ISRN Obstet Gynecol 2011; 2011: 453190
  3. Disaia PJ, Creasman WT. Gestational trophoblastic neoplasia In: Clinical Gynecologic oncology, 6th ed.St Louis: Cv Mosb; 2002; 7: 185- 210
  4. Davis JR, Surwit EA, Garay JP, Fartier KJ. Sex assigment in gestational trophoblastic neoplasia. Am J Obstet Gynecology 1984; 148(6): 722-5
  5. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003; 4(11): 670-8
  6. Ghaemmaghami F, Ashraf-Ganjooie T. Gestational trophoblastic neoplasia. Asia-Pacific J Clin Oncol 2006; 2(1): 9-21
  7. Ozalp SS, Yalcın OT, Tanır HM. Hidatiform mole in Turkey from 1932 to 2000. Int J Gynecol Obstet 2001; 73(3): 257-8
  8. Hayashi K, Bracken MB, Freeman DH Jr, Hellenbrand K. Hydatidiform mole in United States (1970-1977): a statistical and theoretical analysis. Am J Epidemiol 1982; 115(1): 67-77
  9. Srivannaboon S, Vatananusara C, Boonyanit S. The incidence of trophoblastic disease in Siriraj Hospital. J Med Assoc Thai 1974; 57(11): 537-42
  10. Gul T, Yılmazturk A, Erden AC. A review of trophoblastic diseases at the medical school of Dicle University. Eur J Obstet Gynecol Reprod Biol 1997; 74(1): 37-40
  11. Cetin M, Balta O, Duran B, Guvenal T, Yanar O. Evaluation of molar pregnancy applied to our clinic. J of C.U Medical Faculty 2004;26: 18-22 12. Gul A, Celebi H. Evaluation of trophoblastic diseases in Yuzuncu Yıl University Medical Faculty Gynecology Clinic. T Klin J Gynecol 2000; 10: 192-5
  12. Kurdoglu M, Kurdoglu Z, Kucukaydın Z, Sahin H, Kamacı M. Gestational trophoblastic diseases: 14 year trial in our clinic. J Turk Soc Obstet Gynecol 2011; 8: 134-9
  13. Oguz S, Karakoca A, Aydogdu T, Gokmen O. Clinical Analysis of 165 gestational trophoblastic disease patients. T Klin Jinekol Obst 2002; 12: 87-94
  14. Kendall A, Gillmore R, Newlands E. Chemotheraphy for trophoblastic disease: current standarts.Curr Opin Obstet Gynecol 2002; 14(1): 33-8
  15. Lurain JR. Pharmacotheraphy of gestational trophoblastic disease. Expert Opin Pharmacother 2003; 4: 2005-17
  16. Hsu CT, Chen TY, Chiu WH, Yang CC, Lai CH, Chancheng CH, et al. Some aspects of trophoblastic diseases peculiar to Taiwan. Am J Obstet Gynecol